and oligodendroglial lineages but the progenitor cell from which PA could arise is still unknown. These tumors affect preferentially the cerebellum and the optic pathway, especially the hypothalamo-chiasmatic (H/C) region. Cerebellar tumors have a benign clinical course whereas H/C PA display a worse prognosis. Understanding the molecular basis responsible for the agressive behavior of H/C PA is prerequisite to set up new molecular targeted therapies. Material and methods: We used microarray technique to compare the transcriptionnal profile of 5 H/C PA and 6 cerebellar PA. Validation of the microarray experiment and comparison of PA with normal developing tissue was done by quantitative RT-PCR and immuno-histochemistry. Finally, we undergone a morphological study of the H/C region in human to identify candidate cell populations at the origin of PA. Results: Cerebellar and H/C PA appeared as two genetically distinct entities as hierarchical clustering perfectly classified the tumors according to their location. Numerous genes involved in cell proliferation, adhesion, migration and brain development were upregulated in H/C PA. These genes were increased in the developing chiasm in comparison with developing cerebellum. The study of fetal H/C region allowed us to identify a unique population of vimentin and GFAP-positive cells highly suggestive of radial glial cells; these cells disappear after birth but a discrete population of vimentin-positive astrocyte-like cells persists just above the optic chiasm in children and adults. Conclusion: Our study provides new molecular and morphological evidences for the developmental origin of PA. We hypothesize that the precursor in the H/C location should be a specialized radial glia cell.

504 Poster

ALK and RPTPβ/ζ mediate HARP TSR-I like domains anti tumour biological actions

Z. Diamantopoulou[1], J. Delbé[2], J. Courty[2], P. Katsoris[1]
[1]University of Patras, Biology, Patras, Greece; [2] Université Paris XII, CNRS UMR 7149, Paris, France

Heparin Affin Regulatory Peptide (HARP) is a 15 kDa growth factor expressed in various tissues and cell lines. HARP participates in multiple biological actions including the induction of cellular proliferation, migration and angiogenesis, and it is thought to be involved in carcinogenesis. Despite the fact that Anaplastic Lymphoma Kinase (ALK), Receptor Protein Tyrosine Phosphatase (RPTPβ/ζ), and N-syndecan have been characterized as HARP receptors, HARP signal transduction pathway remains unclear.

Recently, our laboratory identified and characterized several HARP proteolytic fragments with biological activities similar or opposite to that of HARP and proposed that the biological activity of this growth factor is mainly attributed to the two central domains of the molecule as well as its C-terminal region. In an attempt to understand the structure/function relationship of HARP, we investigated the biological actions of P13-39 and P65-97, two synthetic peptides that correspond to a part of the N-terminal and C-terminal TSR-I motif of HARP, respectively. Our results show that both P13-39 and P65-97 inhibit in vitro migration and anchorage-dependent and –independent proliferation in PC3 cells, a human cancer prostate cell line. In addition, P13-39 and P65-97 inhibit angiogenesis in vivo, as determined by the chicken embryo CAM assay. ALK and RPTPβ/ζ mediated P65-97 and P13-39 biological actions respectively, as demonstrated by selective knockdown of ALK and RPTPβ/ζ expression with shRNA. Investigation of the transduction mechanisms revealed that these peptides affect the activation of SRC-kinase, AKT, and ERK1/2.

In conclusion, it seems that HARP interacts with ALK and RPTPβ/ζ through its C-terminal and N-terminal TSR-I motif, respectively. Each receptor triggers a signal transduction pathway that leads to specific biological cell responses.

505 Poster

In vitro analysis of population specific splicing variants of BRCA1 gene

J. Sevcik[1], E. Vondruskova[1], P. Pohlreich[1], F. Lhota[1], E. Matouskova[1], E. Bursikova[1], Z. Kleibl[1]
[1]Charles University in Praque, Biochemistry & Experimental Oncology, Prague, Czech Republic

Background: The BRCA1 is involved in DNA repair and its gene mutations are responsible for the development of majority of hereditary breast and ovarian cancer cases in the Czech Republic. Approximately 65% of BRCA1 mutations occur in form of population specific alterations, however, the remaining represent rare or unique genetic changes. Moreover, during mutation screening were detected numerous splicing aberrations of unknown clinical significance in both heterozygotic and homozygotic form. To test their biological importance we developed in vitro system.

Methods: Using pSUPER and pcDNA 3.1 vectors the stable clones of breast adenocarcinoma cell line MCF-7 expressing population-specific BRCA1 splicing variants, anti wtBRCA1 shRNA or combination of these were generated by puromycine-selection following calcium phosphate transfection. The shRNA sequences were targeted to sequences missing in splicing variants. The up and down-regulation of BRCA1 gene was scored by qPCR on the mRNA level and by Western blotting on the protein level. At least two different clones for each BRCA1 splicing variant were analyzed in triplicates. The recovery of cell growth following gamma irradiation was tested by MTT and flow cytometry.

Results: We successfully established stable clones expressing BRCA1 splicing variants (Del e14-15; Del e14-18; Del e17-19) affecting BRCA1 phosphorylation sites or BRCT domains, stable pSUPER clones down regulating BRCA1 to 10-15% of control cells wtBRCA1 mRNA expression and clones stably expressing splicing variant BRCA1 exons 14-18 del with down regulated wtBRCA1. The cells expressing the BRCA1 splicing variants showed prolonged population-doubling time (~1.5-times), morphological changes and higher viability comparing to controls. The growing patterns of MCF-7 cell with down-regulated wt BRCA1 were not changed, comparing to mock. The growth properties examined in relation to gamma-irradiation induced DNA damage show that while the control cells reacted to gDNA damage by decreasing their growth rate and plating efficiency, growth properties of cells expressing BRCA1 exon 14-18Δ splicing variant with down-regulated wt BRCA1 remained almost unaffected.

Discussion: Our current in vitro results shows that splicing variants of BRCA1 may alter BRCA1 DNA repair capacity, however the molecular mechanism of these changes are currently under investigation.

Acknowledgement: Supported by grant IGA MZCR NR-8345-4

506 Poster

Angiogenic factors in breast cancer

V. Yasasever[1], H. Oguz Soydinc[1], H. Camlica[2], D. Duranyildiz[1], N. Dalay[1]
[1]Istanbul University Oncology Institute, Basic Oncology, Istanbul, Turkey; [2] Istanbul University Oncology Institute, Preventive Oncology Biostatistics and Epidemiology, Istanbul, Turkey

Background: Tumor angiogenesis, the formation of new blood vessels, is one of the most important biologic features that are related to tumor growth and metastasis. In this study, we analyzed the circulating serum levels of potent angiogenic factors, including vascular endothelial growth factor (VEGF), angiogenin and transforming growth factor-beta 1 (TGF-beta1) in breast cancer patients. Materials and methods: The study group consisted of 90 breast cancer patients consecutively presenting to Istanbul University Oncology Institute in a 10-month period and 75 healthy controls. The median age of patients was 49 (24 – 71) years and it was 43 (28 – 69) years for healthy controls. Serum VEGF, angiogenin and TGF-beta1 levels were measured by enyzme -linked immunosorbent assay (ELISA). Data analysis was performed by using SPSS 11. Results: There was no significant difference in the serum VEGF (p=0.156), angiogenin (=0.976) and TGF-beta1 (=0.215) levels between breast cancer patients and the controls. There is a significant correlation between VEGF and angiogenin levels in patients (p<0.001). Significant correlations were observed between the parameters of angiogenin - TGF-beta1 (p<0.001) and TGF-beta1 - VEGF (p<0.001) in the healthy controls. Conclusions: In conclusion, we did not observe significant differences in angiogenic factors between breast cancer patients and controls. Vascular metastasis may be seen earlier in the patients who have increased VEGF and angiogenin values in sera than the others.

507 Poster

Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells

Y. Choi[1], C. Jin[1], C. Park[1], T. Kwon[2]
[1]Dongeui University College of Oriental Medicine, Department of Biochemistry, Busan, South Korea; [2] Keimyung University School of Medicine, Department of Immunology, Taegu, South Korea

Naringenin (NGEN), a flavonoid, has shown cytotoxicity in various human cancer cell lines and inhibitory effects on tumor growth. We determined the effect of ectopic Bcl-2 expression on NGEN-induced apoptosis and whether the small molecule Bcl-2 inhibitor, HA14-1, could increase NGEN sensitivity. Bcl-2 overexpression markedly protected U937 cells from time- and dose-dependent induction of apoptosis by NGEN, as did caspase-3 or caspase-9 inhibitors, and increased their cell survival. Bcl-2 attenuated NGEN induced Bax translocation and cytosolic release of cytochrome c. Co-administration of HA14-1 and NGEN increased apoptosis in U937/Bcl-2 cells by restoring loss of MMP and activation of caspase-3, -9 and cleavage of poly (ADP-ribose) polymerase (PARP). This result indicates Bcl-2 confers apoptosis resistance to NGEN by inhibiting a mitochondrial amplification step in U937 cells. HA14-1 reversed Bcl-2-mediated NGEN